NICE recommends dermatitis treatment for use in NHS England and Wales

NICE has issued a positive Final Appraisal Document (FAD) which recommends tralokinumab, upadacitinib and abrocitinib for use within NHS England and Wales.

NICE recommended these options for the treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic treatment, only if the disease has not yet responded to at least one systemic immunosuppressant, or these are not suitable. 

Atopic dermatitis currently affects approximately 3.5% of adults across Europe. Research from earlier this year found that those living with atopic dermatitis in the UK would be willing to trade 37% of their remaining life span in order to achieve better health.

Tralokinumab is the first high affinity, human monoclonal antibody developed to specifically bind to and inhibit the IL-13 cytokine in adult patients with uncontrolled moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Tralokinumab is available in a 150 mg/mL prefilled syringe for subcutaneous injection with an initial dose of 600mg followed by 300mg every other week. Tralokinumab can be used with or without topical corticosteroids (TCS).

“NICE’s decision to recommend tralokinumab is an important step for those living with moderate-to-severe atopic dermatitis. We are delighted that this recommendation will give those living with the condition in England and Wales access to a new treatment option. This approval represents the latest innovation from LEO Pharma as we continue to support people living with skin conditions. Thank you to all the LEO Pharma employees and our partners, as well as the clinicians and patient organisations who have worked so hard to support this process for patients,” shared Sarah Kleinpeter, Vice President and General Manager of UK and Ireland at LEO Pharma.

Lina Adams